Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharmaCNBC • 12/20/23
Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine MedicinesBusiness Wire • 12/18/23
Patients Regain Weight After They Quit Using Ozempic Rival Zepbound. Here's Why That Makes Eli Lilly Stock an Even Better Buy.The Motley Fool • 12/16/23
Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual MeetingPRNewsWire • 12/12/23
Patients Who Stopped Using Zepbound Experienced ‘Substantial' Weight Regain, Eli Lily's Study SuggestsForbes • 12/11/23
Eli Lilly Stock Falls on Data That Show Patients Who Stopped Zepbound Regained WeightBarrons • 12/11/23
Midday Movers: Cigna Soars After Calling Off Humana Deal, Eli Lilly Falls Following StudyInvestopedia • 12/11/23
Eli Lilly obesity drug patients regained weight after ending treatment: studyProactive Investors • 12/11/23
Eli Lilly Skids, Weighing On Novo Nordisk, On A Key New Finding For Obesity DrugsInvestors Business Daily • 12/11/23